Drug Trial Radar · NCT07036029
NAL ER IPF Respiratory Function and Safety Study
Last checked: Nov 20, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
9
Actual
Start
Aug 21, 2025
Primary completion
Jun 30, 2026
Study completion Jun 30, 2026
Sponsor
- Lead sponsor
- Trevi TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jun 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to assess the safety and tolerability of escalating doses of NAL ER and to evaluate its effect on respiratory function in participants with IPF.
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
NAL ERDrug
Oral tablets
PlaceboDrug
Oral tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Respiratory Function and Safety Assessed by Number of Participants With Increase in End Tidal Partial Pressure of Carbon Dioxide by Capnography (PetCO2) of at Least 10 Millimetres of Mercury (mmHg) From Baseline, or PetCO2>55 mmHg, for at Least 1 MinuteTime frame: Up to Day 6
- Respiratory Function and Safety as Assessed by Number of Participants With a Decrease in Blood Oxygen Saturation (SpO2) to <88% for at Least 1 MinuteTime frame: Up to Day 6
- Respiratory Function and Safety as Assessed by Number of Participants With a Decrease in Respiratory Rate (RR) to <6 Breaths per MinuteTime frame: Up to Day 6
- Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: Up to Day 51
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Mayo Clinic
Rochester, Minnesota
Medicines Evaluation Unit Ltd.
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.